To describe the natural history and clinical outcomes of patients with cancer and Covid19 infection.
Study design & methodology:
Retrospective observational study.
Research will be limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection). Every aspect of this research will be undertaken by staff within a care team using information previously collected in the course of care for their own patients.
Routinely collected clinical data including patients’ demographics, prior medical history, cancer history including prior and current anti-cancer therapy, co-morbidities will be collected in a data collection proforma. Results of routinely collected blood tests, radiologic assessment and therapies received by the patient will also be entered onto the database. Clinical outcomes including response to treatment and patients’ survival will be evaluated in relationship to baseline clinico-pathologic profile.
Duration of Research:
Planned sample size:
Due to the descriptive and retrospective nature of this study, no sample size is required for hypothesis testing. We aim to describe clinical outcomes of consecutively presenting patients with a diagnosis of cancer and SARS-CoV-2 infection and aim to retrieve data on up to 1000 fulfilling eligibility criteria.
Summary of eligibility criteria:
1. Be ≥18 years of age.2. Have a confirmed diagnosis of malignancy of any type.3. Have a confirmed diagnosis of SARS-CoV-2 infection.
Number of study centres: 1
To retrospectively describe the survival of cancer patients affected by SARS-CoV-2 infection.
GENERAL STUDY INFORMATION
Name of sponsor:
Imperial College London
Joint Research Compliance Office
Medical School Building
St Mary’s Campus
London, W2 1PG